GHK-Cu: Route of Administration Shapes the Hippocampal Profile (Mouse Preprint 2026)

What this is about

On May 26, 2026, a paper appeared on the preprint server Research Square that looks at GHK-Cu not from the familiar dermatological perspective, but from the angle of cognitive aging in a rodent model. The contribution was indexed in PubMed on June 5, 2026 (PMID 42245779, DOI 10.21203/rs.3.rs-9520102/v1). The author group is Mazzola et al. from the orbit of the University of Washington.

The core question is posed in a methodical and unusually precise way: does it make a difference by which route the same substance is administered at the same dose, not only for behavior, but for the underlying gene expression program in the hippocampus. The preprint's short answer: yes, and clearly so.

Before we break down the data, one framing point that applies throughout this article: this is a non-peer-reviewed preprint, in other words an advance publication without external review, in an animal model. In the EU, GHK-Cu is a research substance, not approved as a medicinal product. No statements about effect, safety, or use in humans can be derived from this data.

What is GHK-Cu?

GHK is a naturally occurring tripeptide made of the three amino acids glycine, L-histidine, and L-lysine (glycyl-L-histidyl-L-lysine). It is released, among other ways, during the proteolytic breakdown of the matrix protein SPARC and binds copper-II ions with high affinity. In this copper-bound form, GHK-Cu, the peptide is biologically active.

Historically, GHK-Cu has been studied above all in the context of skin, wound healing, and cosmetic research, where it has been a subject of skin regeneration research for decades. The preprint discussed here addresses a different area of investigation, central nervous system aging in a rodent model, and thus sits within a smaller, younger line of research. A predecessor paper from the same research direction (intranasal GHK in aged mice, PMID 38014118, 2023) had already worked with 15 mg/kg over eight weeks and reported learning differences versus saline controls in Y-maze and box-maze tests. The new preprint builds on this setup and places the route of administration at its center.

The study design in detail

The setup allows a clean comparison, because substance and dose are held constant and the variables route of administration and treatment duration are in the foreground. Important for interpretation: because route and duration vary in a coupled fashion here (IP short, IN long), this study alone cannot cleanly separate how much of the differences is due to the route and how much to the treatment duration. That is a structural limitation of the design, not a side detail.

Behavioral findings

In the spatial learning test, the following pattern emerged according to the preprint:

• Intranasal (8 weeks): shorter escape latency across trials 2 to 4, and in both sexes (reported at P less than 0.05). This effect was more consistent and more sustained over the course of training.
• Intraperitoneal (5 days): a transient advantage, limited to males and essentially to trial 2, without a sustained effect and without improvement in females.

The researchers summarize this as a behavioral rescue in both arms, but emphasize that intranasal administration delivered the more robust picture across sexes and trials. The intraperitoneal effect was more of a brief flash than a stable change in the learning trajectory.

Alongside this, immunohistochemistry was analyzed. Here too the routes diverged:

• Intranasal: increased synaptophysin in females (P less than 0.001) and reduced GFAP in both sexes (P less than 0.01). GFAP is a common marker for reactive astrogliosis.
• Intraperitoneal: reduced TGF-beta, GFAP, and MCP-1 in males as well as reduced p21 in females (P less than 0.0001). p21 is a classic senescence marker.

These are different signatures at the tissue level that fit the different behavioral dynamics.

The actual finding: divergent hippocampal programs

The most interesting part of the preprint lies not in behavior, but in the RNA sequencing. Despite a partly overlapping behavioral direction, the two routes were accompanied by partly opposing molecular programs.

Intranasal: suppression of growth and mitochondrial signals. The GSEA of the intranasal animals showed a clear downregulation of oxidative phosphorylation (reported with an NES of about minus 5.44 in males and minus 4.20 in females, FDR less than 0.0001), of the MYC target genes (females NES about minus 4.31), and of the PI3K-AKT-mTOR pathway in females. The direction of these axes, less mTOR growth signal, a dampened oxidative phosphorylation program, conceptually overlaps with patterns discussed in aging research, without the preprint deriving any causal statement from it.

Intraperitoneal: activation of repair and stress response. The intraperitoneal arm showed the opposite sign on several axes: upregulated oxidative phosphorylation (females NES about 4.97, FDR less than 0.001), activated DNA repair programs (NES about 5.58), and likewise upregulated MYC target genes. This is a stress and repair-response signature, not a shutdown of growth signals.

The authors describe this as two different biological modes that lead to a similar behavioral goal: the intranasal route through dampening of growth and mitochondrial signals, the intraperitoneal route through activation of repair and stress response. For research, this dissociation is the actual point: behavioral similarity does not mean molecular similarity here, and the route of administration is a non-trivial variable.

Product mentioned in this article

The copper tripeptide examined in the preprint is listed in our catalog as a research substance. The following card links to the product page with the respective specifications.

GHK-Culongevity

Naturally occurring copper tripeptide complex for skin regeneration and anti-aging research. Stimulates collagen synthesis, accelerates wound healing, and modulates 4000+ genes. Plasma levels decline with age, making it a key target in longevity research.

Context and limitations

A few sober observations on robustness. First, the sample size in such behavioral and sequencing studies is typically small, which limits the statistical power of individual sex subgroups. The reported sex-specific effects (for example synaptophysin only in females, the IP advantage only in males) are interesting, but exactly the kind of finding that needs replication before you give it weight. Second, GSEA signatures are correlations at the pathway level, not mechanistic proof. Third, the opposing direction of oxidative phosphorylation between the arms is striking enough that it calls for independent confirmation before you spin a story out of it about route-specific biology.

The honest summary reads: a methodically well-posed, preliminary finding that shows the route of administration in a rodent model can shape the molecular response to GHK-Cu. No more than that, and that is already remarkable enough to be worth following.

Note on the FDA and the EU status

In the context of new peptide research data, the question of regulatory steps comes up regularly. To clarify: even if a US agency such as the FDA takes a step on a substance, for example an advisory measure or a classification, that is a US matter and not an approval. Such a step changes nothing about the EU status. In the EU, GHK-Cu remains a research substance that is handled exclusively for laboratory purposes. The preprint discussed here contains no regulatory component in any case, this is only a general framing for context.

Frequently asked questions

Sources

1. Mazzola J, Rosenfeld M, Tucker M, Wezeman J, Ladiges W, Liao GY. "Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs." Research Square (Preprint), May 26, 2026. PMID 42245779. DOI 10.21203/rs.3.rs-9520102/v1. https://pubmed.ncbi.nlm.nih.gov/42245779/
2. Preprint predecessor of the same research direction: "Intranasal GHK peptide enhances resilience to cognitive decline in aging mice." bioRxiv, 2023. PMID 38014118. https://pmc.ncbi.nlm.nih.gov/articles/PMC10680828/

---

Note: All substances mentioned in this article are intended exclusively for research purposes (research use only) and not for human consumption (not for human consumption).